<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="58508">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344355</url>
  </required_header>
  <id_info>
    <org_study_id>201504786</org_study_id>
    <nct_id>NCT02344355</nct_id>
  </id_info>
  <brief_title>A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme</brief_title>
  <official_title>Pharmacological Ascorbate Combined With Radiation and Temozolomide in Glioblastoma Multiforme: A Phase 2 Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Iowa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Holden Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Iowa</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial evaluates adding high-dose ascorbate (vitamin C) to standard of care
      treatment of glioblastoma multiforme (a type of brain tumor) in adults. All subjects will
      receive high-dose ascorbate in addition to the standard treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard treatment for glioblastoma multiforme (GBM) involves maximum safe surgical
      resection followed by radiation combined with temozolomide (a chemotherapy pill you take by
      mouth). After radiation, patients receive additional cycles of temozolomide (adjuvant
      chemotherapy).

      Participants will:

        -  receive high doses of intravenous (IV) ascorbate three times a week during the combined
           radiation and chemotherapy phase

        -  receive high doses of intravenous (IV) ascorbate twice a week during adjuvant
           chemotherapy (after radiation)

        -  complete health-related quality of life questionnaires pre-radiation, 4 weeks into
           radiation, 4 weeks after radiation, and then every 3 months. In addition, patients will
           complete neurocognitive testing pre-radiation, 4 weeks into radiation, 4 weeks after
           radiation, and approximately 9 months after initiating radiation therapy.

      The adjuvant chemotherapy portion of this study lasts for 6 months. After that is completed,
      participants will go back to standard therapy for their cancer. Participants will continue
      to have life-long follow-up for this study.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 30, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>monthly up to 5 years post treatment</time_frame>
    <description>From radiation day 1 until date of death from any cause.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>monthly up to 5 years post treatment</time_frame>
    <description>From radiation day 1 to documented disease progression in MRI imaging as described by the RANO criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Event Frequency</measure>
    <time_frame>monthly through 7 months post-radiation</time_frame>
    <description>Categorize and quantify using the Common Terminology Criteria for Adverse Events (CTCAE) v. 4 from radiation day 1 through 7 months post-radiation.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-related Quality of Life (HRQOL)</measure>
    <time_frame>monthly for 3 months, then every 3 months up to 5 years post treatment</time_frame>
    <description>Measure health-related outcomes using the validated EORTC (European Organization for Research and Treatment of Cancer) questionnaires QLQ-C30 and BN-20.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Glioblastoma Multiforme</condition>
  <arm_group>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concomitant therapy:
Radiation therapy, oral temozolomide, and pharmacological ascorbate (ascorbic acid) infusions
Adjuvant therapy:
Oral temozolomide and pharmacological ascorbate (ascorbic acid) infusions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temozolomide</intervention_name>
    <description>oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.
Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.
For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.
If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days.</description>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <other_name>Temodar</other_name>
    <other_name>Temodal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.</description>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <other_name>EBRT</other_name>
    <other_name>XRT</other_name>
    <other_name>external beam radiation therapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ascorbic Acid</intervention_name>
    <description>Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.
After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide.</description>
    <arm_group_label>ascorbate, radiation, temozolomide</arm_group_label>
    <other_name>Vitamin C</other_name>
    <other_name>Ascorbate</other_name>
    <other_name>Pharmacological Ascorbate</other_name>
    <other_name>67457-118-50</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have newly diagnosed (i.e., within 5 weeks), histologically or
             cytologically confirmed glioblastoma multiforme.

          -  Diagnosis must be made by surgical biopsy or excision.

          -  Therapy must begin ≤ 5 weeks after surgery or biopsy

          -  Age ≥ 18 years

          -  ECOG performance status 0-2. (KPS &gt; 50)

          -  Absolute neutrophil count (ANC) ≥ 1500 cells per mm3

          -  Platelets ≥ 100,000 per mm3

          -  Hemoglobin ≥ 8 g/dL

          -  Creatinine ≤ 2.0 mg

          -  Total bilirubin ≤ 1.5 mg/dL

          -  ALT ≤ 3 times the institutional upper limit of normal

          -  AST ≤ 3 times the institutional upper limit of normal

          -  Tolerate one test dose (15g) of ascorbate.

          -  Not pregnant.

        Exclusion Criteria:

          -  Recurrent high grade glioma

          -  G6PD (glucose-6-phosphate dehydrogenase) deficiency.

          -  Patients actively receiving insulin or using a finger-stick glucometer daily for
             blood glucose measurements

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to temozolomide.

          -  Significant co-morbid central nervous system disease, including but not limited to,
             multiple sclerosis.

          -  Patients who are on the following drugs and cannot have a drug substitution:
             warfarin, flecainide, methadone, amphetamines, quinidine, and chlorpropamide.

          -  Prior invasive malignancies (except non-melanomatous skin cancers and carcinoma in
             situ of the cervix or bladder) unless disease free for ≥ 5 years.

          -  Patients who have received prior chemotherapy (including Gliadel wafers) for the
             current glioma.

          -  Prior radiation therapy to the head or neck resulting in overlap of RT fields.

          -  Patients receiving any other investigational agents (imaging agents are acceptable)

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac
             arrhythmia, or psychiatric illness/social situations that would limit compliance with
             study requirements.

          -  Pregnant women.

          -  Breastfeeding women.

          -  Known HIV-positive individuals. High-dose ascorbate acid is a known CYP450 3A4
             inducer, which results in lower serum levels of antiretroviral drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bryan G. Allen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistant Professor, Department of Radiation Oncology, The University of Iowa</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bryan G. Allen, MD, PhD</last_name>
    <phone>319-353-8836</phone>
    <email>bryan-allen@uiowa.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Joseph J Cullen, MD</last_name>
    <phone>319-356-1616</phone>
    <email>joseph-cullen@uiowa.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Holden Comprehensive Cancer Center</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandy Vollstedt, RN, BSN</last_name>
      <phone>319-353-7143</phone>
      <email>sandy-vollstedt@uiowa.edu</email>
    </contact>
    <contact_backup>
      <last_name>Heather Brown, RN, BAN</last_name>
      <phone>319-384-7912</phone>
      <email>heather-brown@uiowa.edu</email>
    </contact_backup>
    <investigator>
      <last_name>John M. Buatti, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Joseph J. Cullen, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Berg, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthew Howard, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremy Greenlee, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>David Hasan, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrick Hitchon, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Garry R Buettner, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark C Smith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carryn M Anderson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wenqing Sun, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Douglas Spitz, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mohammed Milhem, MBBA</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aristides A. Capizzano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 17, 2017</lastchanged_date>
  <firstreceived_date>January 16, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Iowa</investigator_affiliation>
    <investigator_full_name>Allen, Bryan G</investigator_full_name>
    <investigator_title>Assistant Professor, Radiation Oncology</investigator_title>
  </responsible_party>
  <keyword>Ascorbic Acid</keyword>
  <keyword>temozolomide</keyword>
  <keyword>radiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Temozolomide</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Ascorbic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be made available after completion of the trial on on clinicaltrials.gov as well as Project Data Sphere and/or NIH equivalent.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
